FAQ: Quantum BioPharma's Private Placement of Class A Multiple Voting Shares
Summary
Quantum BioPharma Ltd. is conducting a non-brokered private placement of up to 30 Class A multiple voting shares at $25 per share, expected to raise up to $750. This offering, approved by shareholders on September 26, 2025, will restore voting rights to 75.27% and provide general working capital for the company's biopharmaceutical development programs.
What is Quantum BioPharma’s private placement about?
Quantum BioPharma is conducting a non-brokered private placement of up to 30 Class A multiple voting shares at $25 per share, aiming to raise up to $750 in gross proceeds. The offering was approved by shareholders on September 26, 2025, and is expected to be fully subscribed by entities controlled by Zeeshan Saeed and Anthony Durkacz.
Why is this private placement significant for Quantum BioPharma?
This private placement is significant because it will restore the voting rights attached to Class A shares to 75.27%, bringing them nearly back to their original level when the company went public in 2018. Additionally, the proceeds will provide general working capital to support the company’s operations and development programs.
How will the funds from this offering be used?
The proceeds from the private placement will be used for general working capital purposes. This funding will support Quantum BioPharma’s ongoing operations and development of treatments for neurodegenerative, metabolic, and alcohol misuse disorders.
Who is expected to subscribe to this private placement?
The offering is expected to be fully subscribed by entities controlled by Zeeshan Saeed and Anthony Durkacz. These entities will acquire the Class A multiple voting shares, which will significantly increase their voting control in the company.
When was this private placement approved and when will it take effect?
The private placement was approved by shareholders on September 26, 2025. The offering is expected to be completed soon, with the voting rights restoration taking effect upon completion of the placement.
What are Quantum BioPharma’s main areas of focus and development?
Quantum BioPharma focuses on developing treatments for neurodegenerative, metabolic, and alcohol misuse disorders. Through its subsidiary Lucid Psycheceuticals, the company is advancing Lucid-MS, a patented compound that prevents and reverses myelin degradation in preclinical models of multiple sclerosis.
What other business interests does Quantum BioPharma maintain?
Beyond its core biopharmaceutical work, Quantum BioPharma retains 20.11% ownership in Unbuzzd Wellness Inc. and receives royalty payments from unbuzzd(TM) sales. The company also maintains strategic investments through its subsidiary FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
Where can investors find more information about Quantum BioPharma?
Investors can access the latest news and updates relating to QNTM in the company’s newsroom at https://www.investorbrandnetwork.com/clients/quantum-biopharma-ltd/. The full press release for this private placement is available at https://ibn.fm/aicDo.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 270159